Viewing nowCombinationIdaliphin Tablet 80/10 mg (Azilsartan Medoxomil Potassium, Amlodipine Besilate)
Potassium Azilsartan Medoxomil 85.36mg · Amlodipine Besylate 13.889mg
Tablet · Prescription medication · Combination
Celltrion, Inc.

MFDS item code 202502797 · Approved 2025.10.29 · Insurance code 623800400
Treatment of essential hypertension not controlled with monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not sufficiently controlled with monotherapy with either azilsartan medoxomil or amlodipine. This drug effectively lowers blood pressure and helps reduce the risk of cardiovascular complications. It improves patient health through blood pressure management and contributes to the prevention of complications.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). 40/5 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 40 mg or amlodipine 5 mg monotherapy. 40/10 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 40 mg or amlodipine 10 mg monotherapy, or with this medicine 40/5 mg. 80/5 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 80 mg monotherapy. 80/10 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 80 mg or this medicine 80/5 mg. Patients taking the individual components concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Dose adjustment is generally not necessary; however, in elderly patients aged 75 years and older, an initial dose of azilsartan medoxomil 20 mg should be considered, so starting treatment with this medicine is not recommended. No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with mild to moderate hepatic impairment, an initial dose of azilsartan medoxomil 20 mg should be considered, so starting treatment with this medicine is not recommended. For patients with possible salt depletion or intravascular volume depletion (e.g., patients with vomiting or diarrhea or those taking high doses of diuretics), an initial dose of azilsartan medoxomil 20mg should be considered, so starting treatment with this medicine is not recommended.
The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Do not take if there is hypersensitivity to this medication or its components, if pregnant or breastfeeding, if there are severe renal diseases or liver dysfunctions, or if there is severe aortic stenosis or a state of shock. Patients with heart failure or renal function dependent on the renin-angiotensin-aldosterone system should be cautious as this medication may cause worsening renal function or hypotension. Patients with decreased blood volume or low salt levels may experience hypotension when starting this medication, so their conditions should be corrected, or it should be started under strict medical supervision. Patients with hyperkalemia or at risk of elevated serum potassium levels should have regular blood tests, as potassium levels may increase while on this medication. Elderly patients may be at increased risk of hypotension, so treatment should begin with a lower dose and patient conditions should be closely monitored. Dizziness, headaches, hypotension, peripheral edema, and other symptoms may occur during treatment; if these symptoms persist or worsen, consult a doctor. This medication may interact with other antihypertensive agents, diuretics, potassium supplements, etc., so it is essential to inform healthcare providers about any other medications being taken. Dizziness or drowsiness may occur when driving or operating hazardous machinery, so caution is advised. In case of overdose, symptoms such as hypotension or dizziness may occur, so care should be taken not to exceed the recommended dose, and if overdose is suspected, a medical institution should be visited immediately. The safety and efficacy of this medication in children and adolescents under 18 years old have not been established, hence its use is not recommended.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 degree and 30 degrees Celsius. This will help preserve the drug's effectiveness for a longer period.
Bright red oval film-coated tablet
30 tablets/PTP [(15 tablets*2 each)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationPotassium Azilsartan Medoxomil 85.36mg · Amlodipine Besylate 13.889mg
Tablet · Prescription medication · Combination
Celltrion, Inc.
CombinationPotassium Azilsartan Medoxomil 85.36mg · Amlodipine Besylate 6.945mg
Tablet · Prescription medication · Combination
Celltrion, Inc.
CombinationPotassium Azilsartan Medoxomil 42.68mg · Amlodipine Besylate 13.889mg
Tablet · Prescription medication · Combination
Celltrion, Inc.
CombinationPotassium Azilsartan Medoxomil 42.68mg · Amlodipine Besylate 6.945mg
Tablet · Prescription medication · Combination
(Co., Ltd. ) Celltrion
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.